Classical psychedelics for the treatment of depression and anxiety: A systematic review
- PMID: 31382100
- DOI: 10.1016/j.jad.2019.07.076
Classical psychedelics for the treatment of depression and anxiety: A systematic review
Abstract
Background: Depression and anxiety are prevalent psychiatric disorders that carry significant morbidity. Pharmacological and psychosocial interventions are used to manage these conditions, but their efficacy is limited. Recent interest into the use of psychedelic-assisted therapy using ayahuasca, psilocybin or lysergic acid diethylamide (LSD) may be a promising alternative for patients unresponsive to traditional treatments. This review aims to determine the efficacy and tolerability of psychedelics in the management of resistant depression.
Methods: Clinical trials investigating psychedelics in patients with depression and/or anxiety were searched via MEDLINE, EMBASE and PsychINFO. Efficacy was assessed by measuring symptom improvement from baseline, and tolerability was evaluated by noting the incidence and type of adverse effects reported. Risk of bias was assessed.
Results: Seven studies, with 130 patients, were analysed in this review. Three were conducted in patients with depression, two in patients with anxiety and two in patients with both. In a supportive setting, ayahuasca, psilocybin, and LSD consistently produced immediate and significant anti-depressant and anxiolytic effects that were endured for several months. Psychedelics were well-tolerated. The most common adverse effects were transient anxiety, short-lived headaches, nausea and mild increases in heart rate and blood pressure.
Limitations: At present, the number of studies on this subject is very limited; and the number of participating patients within these is also limited as the treatment under investigations is a relatively novel concept.
Conclusions: Though further evidence is required, psychedelics appear to be effective in significantly reducing symptoms of depression and anxiety and are well-tolerated.
Keywords: Anxiety associated with life-threatening disease; Depression; Psychedelics.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
-
Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.Expert Rev Clin Pharmacol. 2018 Sep;11(9):889-902. doi: 10.1080/17512433.2018.1511424. Epub 2018 Aug 23. Expert Rev Clin Pharmacol. 2018. PMID: 30102078 Review.
-
[Efficacy of psychedelics in psychiatry, a systematic review of the literature].Encephale. 2021 Aug;47(4):376-387. doi: 10.1016/j.encep.2020.12.002. Epub 2021 Apr 20. Encephale. 2021. PMID: 33888297 French.
-
Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.J Psychopharmacol. 2022 Jan;36(1):20-30. doi: 10.1177/02698811211044688. Epub 2021 Sep 14. J Psychopharmacol. 2022. PMID: 34519567
-
Psychedelics and Psychedelic-Assisted Psychotherapy.Am J Psychiatry. 2020 May 1;177(5):391-410. doi: 10.1176/appi.ajp.2019.19010035. Epub 2020 Feb 26. Am J Psychiatry. 2020. PMID: 32098487 Review.
-
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.Molecules. 2022 Apr 14;27(8):2520. doi: 10.3390/molecules27082520. Molecules. 2022. PMID: 35458717 Free PMC article. Review.
Cited by
-
Decoupling of cortical activity from behavioral state following administration of the classic psychedelic DOI.Neuropharmacology. 2024 Oct 1;257:110030. doi: 10.1016/j.neuropharm.2024.110030. Epub 2024 Jun 6. Neuropharmacology. 2024. PMID: 38851531
-
Personality traits explain the relationship between psychedelic use and less depression in a comparative study.Sci Rep. 2024 May 3;14(1):10195. doi: 10.1038/s41598-024-60890-1. Sci Rep. 2024. PMID: 38702496 Free PMC article.
-
Single administration of a psychedelic [(R)-DOI] influences coping strategies to an escapable social stress.Neuropharmacology. 2024 Jul 1;252:109949. doi: 10.1016/j.neuropharm.2024.109949. Epub 2024 Apr 16. Neuropharmacology. 2024. PMID: 38636726
-
Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials.Clin Psychopharmacol Neurosci. 2024 May 31;22(2):222-231. doi: 10.9758/cpn.23.1134. Epub 2023 Nov 30. Clin Psychopharmacol Neurosci. 2024. PMID: 38627070 Free PMC article. Review.
-
Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics?Eur Arch Psychiatry Clin Neurosci. 2024 Feb 27. doi: 10.1007/s00406-024-01770-7. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2024. PMID: 38411629 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical